terconazole


Also found in: Dictionary, Wikipedia.
Related to terconazole: Yeast infection

terconazole

 [ter-kon´ah-zōl]
an imidazole derivative used as a topical antifungal agent in treatment of vulvovaginal candidiasis.

terconazole

(ter-kon-a-zole) ,

Terazol-3

(trade name),

Terazol-7

(trade name)

Classification

Therapeutic: antifungals
Pregnancy Category: C

Indications

Treatment of vulvovaginal candidiasis.

Action

Affects the permeability of the fungal cell wall, allowing leakage of cellular contents. Not active against bacteria.

Therapeutic effects

Inhibited growth and death of susceptible Candida, with decrease in accompanying symptoms of vulvovaginitis (vaginal burning, itching, discharge).

Pharmacokinetics

Absorption: 5–16% is systemically absorbed following intravaginal administration.
Distribution: Unknown. Action is primarily local.
Metabolism and Excretion: Negligible with local application.
Half-life: Not applicable.

Time/action profile (plasma concentrations)

ROUTEONSETPEAKDURATION
Intravagunknown6.6 hrunknown

Contraindications/Precautions

Contraindicated in: Hypersensitivity to active ingredients, additives, or preservatives.
Use Cautiously in: Obstetric / / Lactation: Safety not established.

Adverse Reactions/Side Effects

Dermatologic

  • Toxic epidermal necrolysis (life-threatening)

Gastrointestinal

  • abdominal pain

Genitourinary

  • dysmenorrhea
  • irritation
  • itching
  • vulvovaginal burning

Miscellaneous

  • anaphylaxis (life-threatening)
  • fever

Interactions

Drug-Drug interaction

Not known.

Route/Dosage

Vaginal (Adults) Vaginal cream—1 applicatorful (5 g) of 0.4% cream at bedtime for 7 days or 1 applicatorful (5 g) of 0.8% cream at bedtime for 3 days. Vaginal suppositories—1 suppository (80 mg) at bedtime for 3 days.

Availability (generic available)

Vaginal cream: 0.4%, 0.8%
Vaginal suppositories: 80 mg

Nursing implications

Nursing assessment

  • Inspect involved areas of skin and mucous membranes before and frequently during therapy. Increased skin irritation may indicate sensitization and warrant discontinuation of medication.

Potential Nursing Diagnoses

Risk for infection (Indications)
Risk for impaired skin integrity (Indications)

Implementation

  • Consult health care professional for proper cleansing technique before applying medication.
  • Vaginal: Applicators are supplied for vaginal administration.

Patient/Family Teaching

  • Instruct patient to apply medication as directed for full course of therapy, even if feeling better. Therapy should be continued during menstrual period.
    • Advise patient to avoid using tampons or douches while using this product.
    • Instruct patient on proper use of vaginal applicator. Medication should be inserted high into the vagina at bedtime. Instruct patient to remain recumbent for at least 30 min after insertion. Advise use of sanitary napkins to prevent staining of clothing or bedding.
    • Advise patient to consult health care professional regarding intercourse during therapy. Vaginal medication may cause minor skin irritation in sexual partner. Advise patient to refrain from sexual contact during therapy. Advise patient that this medication may weaken latex or rubber contraceptive products. Another method of contraception should be used during treatment.
    • Advise patient to report to health care professional increased skin irritation or lack of response to therapy. A second course may be necessary if symptoms persist.
    • Advise patient to thoroughly clean the applicator after each use.
    • Advise patient to notify health care professional if signs and symptoms of anaphylaxis (hives, shortness of breath, facial swelling) or rash occurs.

Evaluation/Desired Outcomes

  • Decrease in skin irritation and vaginal discomfort. Therapeutic response is usually seen after 1 wk. Diagnosis should be reconfirmed with smears or cultures before a second course of therapy to rule out other pathogens associated with vulvovaginitis. Recurrent vaginal infections may be a sign of systemic illness.

terconazole

/ter·co·na·zole/ (ter-kon´ah-zōl) an imidazoleantifungal used in the treatment of vulvovaginal candidiasis.

terconazole (terkon´əzōl´),

n brand names: Terazol 3, Terazol 7;
drug class: local antifungal;
action: interferes with fungal DNA replication; binds sterols in fungal cell membranes, which increases permeability, leaking of nutrients;
uses: vaginal, vulvar, vulvovaginal candidiasis.
References in periodicals archive ?
Diagnosis: Irritant contact dermatitis (as opposed to allergic contact dermatitis) associated with the use of terconazole and clobetasol.
It showed that clotrimazole, terconazole and miconazole were more effective than nystatin in preventing persistent vaginal infection (RR 0.
On the basis of breakpoints established for other fungi, the case isolate appeared resistant to amphotericin B, 5-flucytosine, fluconazole, and possibly terconazole.
5) Boric acid was compared with nystatin, terconazole, flucytosine, itraconazole, clotrimazole, ketoconazole, fluconazole, buconazole, and miconazole.
Boric acid varied from 40% to 100% N statin 50% Terconazole 70% Flurytosme 90% Itraconazole 90.
In medicine, several potent drugs possessing triazole nucleus have been applied, like, Alprazolam (anxiolytic agent and tranquilizer), Anastrozole, Letrozole, Vorozole (antineoplastics and nonsteroidal competitive aromatase inhibitors), Estazolam (hypnotic, sedative and tranquilizer), Etoperidone (antidepressant), Fluconazole, Itraconazole, Terconazole (antifungal agents), Ribavirin (antiviral agent), Benatradin (diuretic), Rilmazafon (hypnotic, anxiolytic and used in the case of neurotic insomnia), Nefazodone (antidepressant and 5-HT2 A-antagonist), Rizatriptan (antimigraine agent), Trapidil (hypotensive), Trazodone (antidepressant, anxiolytic and selectively inhibits central serotonin uptake) and Triazolam (sedative and hypnotic) [23].
I find terconazole is the most effective medication, and I have patients who will have to use it for 14 days as opposed to a 3- or 7-day course, and others who have to use it twice a day" Dr.
Food and Drug Administration ("FDA") for its Abbreviated New Drug Application ("ANDA") for terconazole vaginal cream, 0.
In April 2004, Taro also received FDA approval of its ANDA for terconazole vaginal cream, 0.
has received approval for terconazole vaginal suppositories, 80 mg.